JP2024511163A - アデノシンデアミナーゼバリアント及びその使用 - Google Patents

アデノシンデアミナーゼバリアント及びその使用 Download PDF

Info

Publication number
JP2024511163A
JP2024511163A JP2023558765A JP2023558765A JP2024511163A JP 2024511163 A JP2024511163 A JP 2024511163A JP 2023558765 A JP2023558765 A JP 2023558765A JP 2023558765 A JP2023558765 A JP 2023558765A JP 2024511163 A JP2024511163 A JP 2024511163A
Authority
JP
Japan
Prior art keywords
adenosine deaminase
variant
amino acid
editing
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511163A5 (cg-RX-API-DMAC7.html
Inventor
ニコル ゴーデッリ、
スン―ジュ イ、
パトリシア、 ロサ フェリシアノ、
ディーター カ ユン ラム、
Original Assignee
ビーム セラピューティクス インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビーム セラピューティクス インク. filed Critical ビーム セラピューティクス インク.
Publication of JP2024511163A publication Critical patent/JP2024511163A/ja
Publication of JP2024511163A5 publication Critical patent/JP2024511163A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005—Cytidine deaminase (3.5.4.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023558765A 2021-03-26 2022-03-25 アデノシンデアミナーゼバリアント及びその使用 Pending JP2024511163A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163166778P 2021-03-26 2021-03-26
US63/166,778 2021-03-26
US202163229057P 2021-08-03 2021-08-03
US63/229,057 2021-08-03
PCT/US2022/022050 WO2022204574A1 (en) 2021-03-26 2022-03-25 Adenosine deaminase variants and uses thereof

Publications (2)

Publication Number Publication Date
JP2024511163A true JP2024511163A (ja) 2024-03-12
JP2024511163A5 JP2024511163A5 (cg-RX-API-DMAC7.html) 2025-04-01

Family

ID=83397962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558765A Pending JP2024511163A (ja) 2021-03-26 2022-03-25 アデノシンデアミナーゼバリアント及びその使用

Country Status (8)

Country Link
US (1) US20240158775A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313118A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024511163A (cg-RX-API-DMAC7.html)
KR (1) KR20240004276A (cg-RX-API-DMAC7.html)
AU (1) AU2022246176A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023019539A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214494A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022204574A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
EP4458963A1 (en) * 2023-05-04 2024-11-06 Technische Universität Dresden Highly active crispr base editors obtained through cas-assisted substrate-linked directed evolution (caslide)
WO2024227911A2 (en) * 2023-05-04 2024-11-07 Technische Universität Dresden Highly active crispr base editors obtained through cas-assisted substrate-linked directed evolution (caslide)
CN120290534A (zh) * 2024-01-10 2025-07-11 上海数因信科智能科技有限公司 腺嘌呤脱氨酶、包含其的碱基编辑器融合蛋白和碱基编辑器系统及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021022043A2 (en) * 2019-07-30 2021-02-04 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
WO2021050571A1 (en) * 2019-09-09 2021-03-18 Beam Therapeutics Inc. Novel nucleobase editors and methods of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015332533B2 (en) * 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
AU2020216484A1 (en) * 2019-01-31 2021-07-29 Beam Therapeutics Inc. Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence
JP7646552B2 (ja) * 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
US20220290121A1 (en) * 2019-08-30 2022-09-15 The General Hospital Corporation Combinatorial Adenine and Cytosine DNA Base Editors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021022043A2 (en) * 2019-07-30 2021-02-04 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
WO2021050571A1 (en) * 2019-09-09 2021-03-18 Beam Therapeutics Inc. Novel nucleobase editors and methods of using same

Also Published As

Publication number Publication date
US20240158775A1 (en) 2024-05-16
WO2022204574A1 (en) 2022-09-29
BR112023019539A2 (pt) 2023-12-05
EP4313118A1 (en) 2024-02-07
CA3214494A1 (en) 2022-09-29
KR20240004276A (ko) 2024-01-11
EP4313118A4 (en) 2025-06-18
AU2022246176A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
JP7717684B2 (ja) 新規核酸塩基エディター及びその使用方法
JP7679311B2 (ja) プログラム可能塩基エディターシステムを用いた一塩基多型編集法
JP7646554B2 (ja) アルファ-1アンチトリプシン不全を治療するための組成物および方法
CN114026237B (zh) 用于治疗1a型糖原贮积病的组成物和方法
US20240158775A1 (en) Adenosine deaminase variants and uses thereof
CN114072509A (zh) 脱氨反应脱靶减低的核碱基编辑器和使用其修饰核碱基靶序列的方法
CN116497067A (zh) 治疗血红素病变的组合物和方法
CA3208612A1 (en) Recombinant rabies viruses for gene therapy
CA3198671A1 (en) Compositions and methods for treating glycogen storage disease type 1a
US20240117345A1 (en) Compositions and methods for treating transthyretin amyloidosis
WO2020231863A1 (en) Compositions and methods for treating hepatitis b
WO2023086953A1 (en) Compositions and methods for the treatment of hereditary angioedema (hae)
CN117561074A (zh) 腺苷脱氨酶变体及其用途
WO2023049935A1 (en) Compositions and methods for treating hepatitis b virus infection
US20240132868A1 (en) Compositions and methods for the self-inactivation of base editors
WO2023039468A1 (en) Viral guide rna delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260721